28 cool health things that started with a Canadian – Regina Leader-Post

Alzheimers in mice

Dr. Peter St George-Hyslopof the Weston Brain Institute identified a number of genes responsible for Alzheimers disease and nerve cell degeneration using mouse models. He has published nearly 400 papers on Alzheimers research.

In the early 2000s, he essentially cured Alzheimers in mice through the discovery that certain types of sugars would block the development of amyloid proteins, one of the hallmarks of Alzheimers.

Genomics

University of Torontos Brenda Andrews pioneered the field of functional genomics and systems biology to discover how genes and their protein products regulate cell function in health and disease. She is also an elected member of the National Academy of Sciences and a specialist in the application of artificial intelligence to personalized medicine.

Kathleen Dickson is a former chief technician from the Montreal Neurological Institute.

John Bergeron is the Emeritus Robert Reford Professor and a Professor of Medicine at McGill University.

Dont miss the latest on COVID-19, reopening and life. Subscribe to Healthings daily newsletterComing Out of COVID.

Read more:
28 cool health things that started with a Canadian - Regina Leader-Post

Global Stem Cell Assay Market with COVID-19 After Effects Analysis by Key Players | GE Healthcare, Promega Corporation, Thermo Fisher Scientific,…

Stem Cell Assay Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

The new report on the globalStem Cell Assay marketpublished by theMarket Research Storeincorporates all the essential facts about the Stem Cell Assay market. This aids different industry players along with new market entrants to open new gateways for the Stem Cell Assay market on a global platform. Through in-depth research and data obtained from the reliable database the qualitative and the quantitative data of the Stem Cell Assay market has been updated based on the current market conditions owing toCOVID-19. The overall market conditions have been affected due to the pandemic. The trading conditions and the economy crisis have affected the Stem Cell Assay market. The information in the Stem Cell Assay market report is updated and precise thus the clients will be able to relate themselves to the current market scenario.

Request Free Sample Copy of Stem Cell Assay Market Research Report@http://www.marketresearchstore.com/report/global-stem-cell-assay-market-report-2019-industry-442702#RequestSample

The Stem Cell Assay market report also encompasses the details about all the market players that are operating in the Stem Cell Assay market. The market players includeGE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies.

The market analysis in the Stem Cell Assay market study starts with the market definition and scope. In the next section, there is a brief discussion about the target audience of the market. In the later section, a detailed information about the market growth factors and limitations are discussed along with the market opportunities and challenges that are being faced owing to arise of the pandemic. Research tools and methodologies were used while analyzing the Stem Cell Assay market.

Read Detailed Index of full Research Study at::http://www.marketresearchstore.com/report/global-stem-cell-assay-market-report-2019-industry-442702

The major section that covers the overall market description is the market segmentation. The Stem Cell Assay market includes segments{Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other}; {Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other}. To study any market in detail the major components that need to be analyzed are its product type, application, end-use, the solution and the services that are offered. Details about all these segments helps better understand the market size and demand. Every aspect of every single segment was studied carefully and the impact of COVID-19 was also taken into consideration. Both numerical data and subjective information about every segment is included for better understanding. The regional presence of the Stem Cell Assay market is also included. The current market condition in each regions is explained thoroughly as to how the pandemic has affected the Stem Cell Assay market demand in a particular region.

Major Advantages for Stem Cell Assay Market:

1. Well-organized description of the international Stem Cell Assay market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas. 2. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Stem Cell Assay industry. 3. The Stem Cell Assay market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis. 4. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global Stem Cell Assay market. 5. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

If Any Inquiry of Stem Cell Assay Report:http://www.marketresearchstore.com/report/global-stem-cell-assay-market-report-2019-industry-442702#InquiryForBuying

Go here to see the original:
Global Stem Cell Assay Market with COVID-19 After Effects Analysis by Key Players | GE Healthcare, Promega Corporation, Thermo Fisher Scientific,...

Lungs in Vitro Market 2020 Opportunities, Growth Analysis, Trends and Forecast by 2024 | ATCC, Lonza, Epithelix – 3rd Watch News

Competitive Market Research Report on Global Lungs in Vitro Market with focus on Industry Analysis, Growth Opportunities, Risk Analysis, Current Trends, Competitive Landscape, Investment Strategies and Forecast by 2024.

The report contains in-depth information on all the key aspects of the global Lungs in Vitro market. This report contains important data such as facts & figures, market research, market analysis, SWOT analysis, competitive landscape, regional analysis and future growth prospects. The report also contains qualitative and quantitative research which gives you a detailed analysis of the global Lungs in Vitro market. The report is perfect as you can see information on the recent developments, based on which you can make risk assessments and investments in the Lungs in Vitro industry.

Get The Sample Report PDF with Detail TOC & List of [emailprotected]https://marketresearchport.com/request-sample/5147

Leading Companies Covered:

ATCC, Lonza, Epithelix, Mattek, Emulate, Mimetas, Tissuse, Insphero, Cn Bio

This global Lungs in Vitro market research report has data of all the leading players operating in the industry. From their market shares in the industry, to their growth plans, recent development status, all important information has been compiled in the report to let you get an insightful look at the top players operating in the industry. The report includes the forecasts, analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry players.

Market Research is Further Divided into Following Segments:

Market Segmentation by Product Types: 2D Cell Models, 3D Cell Models, Commercial 3D Cell Models, Inhouse 3D Cell Models

Market Segmentation by Applications: Drug Screening, Toxicology, 3D Model Development, Basic Research, Physiologic Research, Stem Cell Research, Regenerative Medicine

Regions Mentioned in the Global Lungs in Vitro Market:

The Middle East and Africa North America South America Europe Asia-Pacific Middle East Oceania Rest of the World

The data of the market research report has been studied, compiled and corroborated by leading industry experts and established authors. The format followed in the report is in accordance with most international market research reports. However, if you have any specific requirements, just get in touch with us, and we will customize the report accordingly as per your needs.

Do Enquiry For Customized Report as per Your [emailprotected]https://marketresearchport.com/enquiry-before-buying/5147

Table of Content: 1 Industry Overview of Lungs in Vitro 1.1 Brief Introduction of Lungs in Vitro 1.1.1 Definition of Lungs in Vitro 1.1.2 Development of Lungs in Vitro Industry 1.2 Classification of Lungs in Vitro 1.3 Status of Lungs in Vitro Industry 1.3.1 Industry Overview of Lungs in Vitro 1.3.2 Global Major Regions Status of Lungs in Vitro

2 Industry Chain Analysis of Lungs in Vitro 2.1 Supply Chain Relationship Analysis of Lungs in Vitro 2.2 Upstream Major Raw Materials and Price Analysis of Lungs in Vitro 2.3 Downstream Applications of Lungs in Vitro

3 Manufacturing Technology of Lungs in Vitro 3.1 Development of Lungs in Vitro Manufacturing Technology 3.2 Manufacturing Process Analysis of Lungs in Vitro 3.3 Trends of Lungs in Vitro Manufacturing Technology

4 Major Manufacturers Analysis of Lungs in Vitro 4.1 Company 1 4.1.1 Company Profile 4.1.2 Product Picture and Specifications 4.1.3 Capacity, Production, Price, Cost, Gross and Revenue 4.1.4 Contact Information 4.2 Company 2 4.2.1 Company Profile 4.2.2 Product Picture and Specifications 4.2.3 Capacity, Production, Price, Cost, Gross and Revenue 4.2.4 Contact Information 4.3 Company 3 4.3.1 Company Profile 4.3.2 Product Picture and Specifications 4.3.3 Capacity, Production, Price, Cost, Gross and Revenue 4.3.4 Contact Information 4.4 Company 4 4.4.1 Company Profile 4.4.2 Product Picture and Specifications 4.4.3 Capacity, Production, Price, Cost, Gross and Revenue 4.4.4 Contact Information 4.5 Company 5 4.5.1 Company Profile 4.5.2 Product Picture and Specifications 4.5.3 Capacity, Production, Price, Cost, Gross and Revenue 4.5.4 Contact Information 4.6 Company 6 4.6.1 Company Profile 4.6.2 Product Picture and Specifications 4.6.3 Capacity, Production, Price, Cost, Gross and Revenue 4.6.4 Contact Information 4.7 Company 7 4.7.1 Company Profile 4.7.2 Product Picture and Specifications 4.7.3 Capacity, Production, Price, Cost, Gross and Revenue 4.7.4 Contact Information 4.8 Company 8 4.8.1 Company Profile 4.8.2 Product Picture and Specifications 4.8.3 Capacity, Production, Price, Cost, Gross and Revenue 4.8.4 Contact Information 4.9 Company 9 4.9.1 Company Profile 4.9.2 Product Picture and Specifications 4.9.3 Capacity, Production, Price, Cost, Gross and Revenue 4.9.4 Contact Information 4.10 Company ten 4.10.1 Company Profile 4.10.2 Product Picture and Specifications 4.10.3 Capacity, Production, Price, Cost, Gross and Revenue 4.10.4 Contact Information

5 Global Productions, Revenue and Price Analysis of Lungs in Vitro by Regions, Manufacturers, Types and Applications 5.1 Global Production, Revenue of Lungs in Vitro by Regions 2014-2019 5.2 Global Production, Revenue of Lungs in Vitro by Manufacturers 2014-2019 5.3 Global Production, Revenue of Lungs in Vitro by Types 2014-2019 5.4 Global Production, Revenue of Lungs in Vitro by Applications 2014-2019 5.5 Price Analysis of Global Lungs in Vitro by Regions, Manufacturers, Types and Applications in 2014-2019

6 Global and Major Regions Capacity, Production, Revenue and Growth Rate of Lungs in Vitro 2014-2019 6.1 Global Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.2 Asia Pacific Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.3 Europe Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.4 Middle East & Africa Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.5 North America Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.6 Latin America Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019

7 Consumption Volumes, Consumption Value, Import, Export and Sale Price Analysis of Lungs in Vitro by Regions 7.1 Global Consumption Volume and Consumption Value of Lungs in Vitro by Regions 2014-2019 7.2 Global Consumption Volume, Consumption Value and Growth Rate of Lungs in Vitro 2014-2019 7.3 Asia Pacific Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.4 Europe Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.5 Middle East & Africa Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.6 North America Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.7 Latin America Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.8 Sale Price Analysis of Global Lungs in Vitro by Regions 2014-2019

8 Gross and Gross Margin Analysis of Lungs in Vitro 8.1 Global Gross and Gross Margin of Lungs in Vitro by Regions 2014-2019 8.2 Global Gross and Gross Margin of Lungs in Vitro by Manufacturers 2014-2019 8.3 Global Gross and Gross Margin of Lungs in Vitro by Types 2014-2019 8.4 Global Gross and Gross Margin of Lungs in Vitro by Applications 2014-2019

9 Marketing Traders or Distributor Analysis of Lungs in Vitro 9.1 Marketing Channels Status of Lungs in Vitro 9.2 Marketing Channels Characteristic of Lungs in Vitro 9.3 Marketing Channels Development Trend of Lungs in Vitro

10 Global and Chinese Economic Impacts on Lungs in Vitro Industry 10.1 Global and Chinese Macroeconomic Environment Analysis 10.1.1 Global Macroeconomic Analysis and Outlook 10.1.2 Chinese Macroeconomic Analysis and Outlook 10.2 Effects to Lungs in Vitro Industry

11 Development Trend Analysis of Lungs in Vitro 11.1 Capacity, Production and Revenue Forecast of Lungs in Vitro by Regions, Types and Applications 11.1.1 Global Capacity, Production and Revenue of Lungs in Vitro by Regions 2019-2024 11.1.2 Global and Major Regions Capacity, Production, Revenue and Growth Rate of Lungs in Vitro 2019-2024 11.1.3 Global Capacity, Production and Revenue of Lungs in Vitro by Types 2019-2024 11.2 Consumption Volume and Consumption Value Forecast of Lungs in Vitro by Regions 11.2.1 Global Consumption Volume and Consumption Value of Lungs in Vitro by Regions 2019-2024 11.2.2 Global and Major Regions Consumption Volume, Consumption Value and Growth Rate of Lungs in Vitro 2019-2024 11.3 Supply, Import, Export and Consumption Forecast of Lungs in Vitro 11.3.1 Supply, Consumption and Gap of Lungs in Vitro 2019-2024 11.3.2 Global Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.3 North America Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.4 Europe Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.5 Asia Pacific Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.6 Middle East & Africa Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.7 Latin America Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024

12 Contact information of Lungs in Vitro 12.1 Upstream Major Raw Materials and Equipment Suppliers Analysis of Lungs in Vitro 12.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Lungs in Vitro 12.1.2 Major Equipment Suppliers with Contact Information Analysis of Lungs in Vitro 12.2 Downstream Major Consumers Analysis of Lungs in Vitro 12.3 Major Suppliers of Lungs in Vitro with Contact Information 12.4 Supply Chain Relationship Analysis of Lungs in Vitro

13 New Project Investment Feasibility Analysis of Lungs in Vitro 13.1 New Project SWOT Analysis of Lungs in Vitro 13.2 New Project Investment Feasibility Analysis of Lungs in Vitro 13.2.1 Project Name 13.2.2 Investment Budget 13.2.3 Project Product Solutions 13.2.4 Project Schedule

14 Conclusion of the Global Lungs in Vitro Industry 2019 Market Research Report

About Us: Market Research Port is one of the best report resellers in the market bringing to you accurate and trustworthy market research reports by reputed publishers. Our trusted publishers have compiled their reports and findings after painstaking research and studies, set up against varied business parameters. Each report is detailed and then vetted for accuracy by industry experts. In each report, you will find deep analysis, risk analysis, market forecasts, emerging trends, different market segments, technological advancement and its impact, and a multitude of economic factors, giving you the most comprehensive market research report. You get many advantages with such comprehensive reports.

Contact Us: Market Research Port, Brighton Street, Providence, Rhode Island 02929, United States Contact No: +1 401 433 7610 Email: [emailprotected] Website: https://marketresearchport.com/

See the original post here:
Lungs in Vitro Market 2020 Opportunities, Growth Analysis, Trends and Forecast by 2024 | ATCC, Lonza, Epithelix - 3rd Watch News

How COVID-19 Pandemic Will Impact Australia & New Zealand Research Antibodies Market Business Opportunity, And Growth 2020-2026 – 3rd Watch News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Australia & New Zealand Research Antibodies market.

Trusted Business Insights presents an updated and Latest Study on Australia & New Zealand Research Antibodies Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Australia & New Zealand Research Antibodies market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Australia & New Zealand Research Antibodies Market Size Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Australia & New Zealand Research Antibodies Market

The Australia & New Zealand research antibodies market size was valued at USD 98.4 million in 2018 and is anticipated to grow at a CAGR of 8.4% during the forecast period. Rise in the number of initiatives being undertaken by the Australian government to advance the biotechnology sector is expected to fuel the growth in the country. In May 2019, Federal Labor offered businesses an R&D tax offset for collaborating with science-based agencies and universities, such as The Commonwealth Scientific and Industrial Research Organisation (CSIRO), to promote innovation and knowledge in biotechnology sector. In addition, a 10% tax can be added to the calculated tax offset if a business is collaborating with any public institution. This plan would help in increasing R&D investments in Australia to 3% of GDP by 2030 and is expected to act as a key tool for fostering an alliance between research and industry, thereby improving industrial capabilities in Australia. R&D tax incentive in Australia has encouraged biotechnology companies in the region to conduct R&D. For instance, in 2018, Shape Pharmaceuticals, Inc. supported R&D investments in Australian biotechnology industry by conducting clinical trials to study the effect of SHP-141 on patients diagnosed with psoriasis. These tax incentives help companies achieve cost advantage while selecting clinical trial sites for R&D processes.

Rise in R&D investments by the government is also expected to boost the market. In 2018, the Victorian government allocated USD 1.5 million for establishment of an Advanced Biotechnology Manufacturing Platform to enhance production of antibodies, vaccines, stem cells, and growth factors, among others, for testing in human clinical trials. This facility would enable various Australian biotechnology companies to conduct R&D in the state, thereby generating jobs and propelling growth of various companies currently conducting clinical trials in Victoria. The government is also promoting development of the biotechnology sector through Future Industries Fund. Growth in stem cell and neurobiology-based research is expected to boost the market over the forecast period. The Center of Research Excellence in Neuromuscular Disorders Australia is a wide collaboration of neuromuscular experts, who use advanced technologies and approaches in science & medicine to improve diagnosis. In addition, it aims to transform treatment to effective therapy of neurological diseases from compassionate management. The Australian Neuromuscular Network was formed in the year 2010 by the Center of Research Excellence in Neuromuscular Disorders along with other neuromuscular specialists, scientists, and professionals across New Zealand and Australia. Rise in the prevalence of neurological disorders is expected to boost the market. According to the Neurological Foundation of New Zealand, by 2051, about one-third of the population in New Zealand will be 65 years and above. The prevalence of dementia is therefore expected to increase, leading to a rise in R&D pertaining to treatment for various neurological disorders. However, stringent government regulations that can limit research activities are expected to restrain market growth.

Product Insights of Australia & New Zealand Research Antibodies Market

On basis of product, Australia & New Zealand research antibodies market is segmented into primary and secondary antibodies. Primary antibodies held the largest share and is anticipated to witness the highest CAGR owing to rise in adoption of reagents developed using antibodies, due to the various benefits associated with them such as greater specificity, easy availability, and suitability in various research applications. Similarly, primary antibodies are anticipated to grow at a faster rate during the forecast period due to varied applications in research. In addition, rise in prevalence of chronic diseases, such as diabetes, cancer, and Alzheimers disease, is leading to an increase in adoption of primary antibodies. Increasing R&D in the country is further anticipated to boost the adoption of secondary antibodies as well. Thus, rising adoption of these antibodies in research for development of alternative therapies is anticipated to create significant demand for these products over the forecast period. End-use Insights Pharmaceutical & biotechnology companies held the largest share of the end-use segment in 2018, which can be attributed to increase in adoption of antibodies in drug development and research organizations. Contract research organizations are anticipated to grow at a lucrative CAGR during the forecast period owing to cost-effectiveness.

The academic & research institutes segment is expected to witness constant growth owing to the presence of various academic research groups that are involved in the study of complex biological systems using advanced reagents. Benefits such as greater understanding of biological processes and complex systems are anticipated to create growth opportunities in the segment. Contract research organizations are anticipated to grow at a lucrative CAGR during the forecast period. Majority of the companies prefer CROs owing to the various advantages associated with contract services. These benefits include cost advantage, increased efficiency of services, and enhanced productivity, which help a company focus on its core expertise.

Type Insights of Australia & New Zealand Research Antibodies Market

On the basis of antibody type, the market is segmented into monoclonal and polyclonal antibodies. Monoclonal antibodies held the largest market share due to increase in research on genomics and personalized medicine, which has led to increase in the use of these antibodies. As monoclonal antibodies are relatively cost-effective, they are anticipated to grow at a higher rate than polyclonal antibodies. Polyclonal antibodies have several advantages over monoclonal in various diagnostic settings. Polyclonal antibodies are often the most preferred option in routine laboratory tests such as Enzyme-Linked Immunosorbent Assay (ELISA), microarray assays, western blotting, flow cytometry, and immunohistochemistry. Their production does not require skilled professionals, and large batches can be produced as per client requirements. These antibodies can recognize multiple antigens on one epitope and can therefore be utilized in the study of various diseases ranging from cancer to metabolic Polyclonal antibodies are relatively inexpensive in comparison with monoclonal antibodies, which may fuel their demand in low-budget and non-funded research projects. However, polyclonal antibodies can differ from batch to batch depending upon manufacturing and quality control process. These antibodies can recognize multiple epitopes, thus increasing the probability of nonspecific antigen binding.

Technology Insights of Australia & New Zealand Research Antibodies Market

On the basis of technology, the Australia & New Zealand research antibodies market is segmented into western blotting, immunoprecipitation, immunochemistry, ELISA, immunofluorescence, flow cytometry, and other technologies. Western blotting held the largest share of the technology segment in 2018 owing to rising demand for rapid diagnostic methods. On the other hand, technical upgradation is anticipated to create growth prospects for technologies in pipeline. ELISA is anticipated to witness the highest CAGR during the forecast period owing to conventional use of polyclonal antibodies in sandwich ELISA. ELISA is an analytical test that essentially uses antibodies to identify substances in samples. These tests are most often used to accurately diagnose diseases, such as AIDS, Lyme disease, syphilis, pernicious anemia, Rocky Mountain spotted fever, squamous cell carcinoma, chickenpox, shingles, and other bacterial & viral infections. Western blotting held the largest share in 2018 owing to rise in prevalence of diseases with limited number of treatment options. Western blotting offers high accuracy and sensitivity and is considered a gold standard for testing. In addition, increase in government initiatives to fund research activities is one of the factors contributing to the highest market share held by this segment, as it is conventionally used in research laboratories. Source Insights The mouse segment held the largest share in 2018 as mice are convenient to use during production of antibodies for research purposes and have wide range of applications. Others segment is expected to grow exponentially, as it has a wide range of applications. The use of murine monoclonal antibodies is increasing in various end-use settings, which is expected to positively impact market growth. Mice have been predominantly used in production of antibodies. The structural similarities in mice and human antibodies is a prime factor responsible for high adoption. Cost-effectiveness and the ability to multiply quickly are among the factors fueling growth of this segment. Moreover, mouse-derived monoclonal and polyclonal antibodies are relatively easier to produce and possess greater specificity. Technological advancements in the development processes of these products, such as hybridoma technology that aids in production of monoclonal antibodies in specialized cells, are further augmenting demand for mouse antibodies. Rabbits are also extensively used for production of antibodies, owing to various advantages such as higher affinity and specificity in comparison with antisera obtained from other animal hosts. Higher specificity of these products makes them ideal for use in detection of small molecules, such as pollutants; toxins; hormones; drugs; nonprotein targets, such as carbohydrates & lipids; and post-translational alterations such as phosphorylation.

Application Insights of Australia & New Zealand Research Antibodies Market

Oncology held the largest share of the application segment in 2018. The largest share can be attributed to growing prevalence of cancer, which leads to an increase in the need for R&D pertaining to advanced therapeutics. On the other hand, stem cell is anticipated to witness lucrative CAGR during the forecast period owing to significant increase in stem cells research. Rising prevalence of infectious diseases, growing geriatric population, decreasing immunity levels, and rising awareness among people about communicable diseases are some of the high impact-rendering drivers of the market. Growing incidence of autoimmune diseases coupled with limited presence of advanced therapeutics is predominantly driving segment growth. Significant advancements in immunology research have boosted adoption of research antibodies in the recent years. Oncology accounted for the largest share of research antibodies in 2018.The segment is also anticipated to grow at a considerable CAGR owing to increasing incidence of cancer. According to WHO, the number of new cancer cases is anticipated to increase by approximately 70.0% in the next two decades. Monoclonal antibodies are also used for diagnosis of lymphoid & myeloid malignancies, tissue typing, and immunological intervention using passive antibody. Owing to the steady increase in the demand for transplantable tissues and low-quality donor cells, stem cell research segment is expected to grow. Moreover, increasing adoption of cell isolation and culture, which involves use of research antibodies, is further anticipated to broaden segment growth prospects.

Market Share Insights of Australia & New Zealand Research Antibodies Market

Some major players in this market are PerkinElmer, Inc.; F.Hoffmann La Roche Ltd.; Thermo Fisher Scientific; Merck Millipore; Bio-Rad Laboratories; Abcam PLC; BD; Lonza Group; Cell Signaling Technology, Inc.; and Agilent Technologies. Increase in the number of products launched by market players is expected to fuel market growth. For instance, in April 2019, Bio-Rad launched a range of isotype-specific secondary antibodies-IgG1, IgG2a, and IgG2b. These products are used to offer specificity when used in ELISA, imaging, western blotting, and flow cytometry, among others, as well as for improved signaling. Mergers & acquisitions and collaborations are some of the other strategic initiatives undertaken by leading players to gain market share, for instance, Abcam Plc acquired Calico Biolabs. This initiative helped the company expand its product portfolio through the addition of high-quality recombinant rabbit monoclonal antibodies for immunohistochemistry. As per the agreement, Abcam was to also expand its custom rabbit monoclonal antibody production. These factors are further anticipated to aid growth during the forecast period.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Australia & New Zealand Research Antibodies Market Research Report This report forecasts revenue growth at country level and provides an analysis on the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the Australia & New Zealand research antibodies market report on the basis of product, type, technology, source application, end use, and country:

Product Outlook (Revenue, USD Million, 2019 2030)

Primary

Secondary

Type Outlook (Revenue, USD Million, 2019 2030)

Monoclonal Antibodies

Polyclonal Antibodies

Technology Outlook (Revenue, USD Million, 2019 2030)

Immunohistochemistry

Immunofluorescence

Western Blotting

Flow Cytometry

Immunoprecipitation

ELISA

Others

Source Outlook (Revenue, USD Million, 2019 2030)

Mouse

Rabbit

Goat

Others

Application Outlook (Revenue, USD Million, 2019 2030)

Infectious Diseases

Immunology

Oncology

Stem Cells

Neurobiology

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Academic & Research Institutes

Contract Research Organizations

Pharmaceutical & Biotechnology Companies

Quick Read Table of Contents of this Report @ Australia & New Zealand Research Antibodies Market Size Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

See the article here:
How COVID-19 Pandemic Will Impact Australia & New Zealand Research Antibodies Market Business Opportunity, And Growth 2020-2026 - 3rd Watch News

Biopreservation Market Worth $4.9 Billion by 2025 | Key Players Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany) and Avantor, Inc. (US) -…

ThermoGenesis Holdings, Inc. (US), Bio-Techne Corporation (US), BioLife Solutions, Inc. (US), Exact Sciences Corporation (US), (US), Worthington Industries, Inc. (US), and Chart Industries, Inc. (US) are some key players in Biopreservation Market.

Therapeutic applications held the largest share of the biopreservation media and equipment market, by application.

According to the new market research reportBiopreservation Market by Type (Media (Sera), Equipment (Thawing Equipment, Alarms, Freezers)), Biospecimen (Human Tissue, Stem Cells, Organs), Application (Therapeutic, Research, Clinical Trials), End User (Hospitals, Biobank) Global Forecast to 2025, published by MarketsandMarkets, the Biopreservation Market is projected to reachUSD 4.9 billionby 2025 fromUSD 3.1 billionin 2020, at a CAGR of 9.1% between 2020 and 2025.

Increasing R&D investments, advances in biobanking and the growing trend of conserving cord blood stem cells of newborns, rising investments in regenerative medicine research, and the increasing demand for personalized medicine are the major factors driving the growth of the biopreservation media and equipment market.

The biopreservation media segment accounted for the largest share of the biopreservation media and equipment market.

Based on type, the biopreservation media and equipment market is segmented into biopreservation media and equipment. The biopreservation media segment accounted for the largest share of the global biopreservation media and equipment market in 2019. The large share of this segment is attributed to the increasing research activities in stem cell therapy, regenerative medicine, and personalized medicine.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=842

The human tissue samples segment accounted for the largest share of the biopreservation media and equipment market in 2019.

On the basis of biospecimen, the biopreservation media and equipment market is segmented into human tissue samples, organs, stem cells and other biospecimens. The human tissue samples segment accounted for the largest share of the global biopreservation media and equipment market in 2019. The large share of this segment is attributed to the increasing number of biobanks and growth in R&D spending for life science research.

North Americato dominate the biopreservation media and equipment market during the forecast period

In 2019,North Americadominated the biopreservation media and equipment market, followed byEurope. The major factors driving the growth of this market include increasing research activities in the field of regenerative medicine, rising R&D investment in life sciences research and growing awareness of personalized medicine.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=842

The prominent players in this market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Avantor, Inc. (US) ThermoGenesis Holdings, Inc. (US), Bio-Techne Corporation (US), BioLife Solutions, Inc. (US), Exact Sciences Corporation (US), (US), Worthington Industries, Inc. (US), and Chart Industries, Inc. (US).

Media Contact

Company Name: MarketsandMarkets

Contact Person: Mr. Aashish Mehra

Email: Send Email

Phone: 18886006441

Address: 630 Dundee Road Suite 430

City: Northbrook

State: IL 60062

Country: United States

Website: https://www.marketsandmarkets.com/Market-Reports/biopreservation-media-storage-equipment-market-842.html

Read more from the original source:
Biopreservation Market Worth $4.9 Billion by 2025 | Key Players Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany) and Avantor, Inc. (US) -...

Stem Cell Therapy Market Share Research By Applications And Regions – News.MarketSizeForecasters.com

The study titled Global Stem Cell Therapy Market Research Report includes detailed research undertaken by analysts as well as an in-depth analysis of the global market. A detailed, highly extensive study of this market alongside pivotal aspects that may impact the commercialization graph of this industry has been given in the study.

As per the latest research report, the global Stem Cell Therapy Market is anticipated to depict a CAGR of 10.2% through 2025, having recorded a valuation of 7.8 billion in 2018.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/3331

By 2025, the Stem Cell Therapy Market is expected to hit a remuneration of 15 billion. An extremely definite evaluation of the global market in terms of qualitative as well as quantitative analysis has been covered in this report. The myriad aspects of this industry, having considered its historical and forecast data have been enlisted in the study. Also, the research report is inclusive of substantial details with regards to an efficient SWOT analysis, PESTEL analysis, and Porters five force model of the market.

The Stem Cell Therapy Market report coverage includes numerous aspects like the market size, geographical growth opportunities, important vendors in the market, driving factors and constraints, segmental evaluation, and competitive landscape.

The report intends to enlist myriad updates and data with regards to the market alongside various growth opportunities which may help the global industry expand at an appreciable rate. An in-depth summary of the Stem Cell Therapy Marketcombined with a well-defined set of market definitions as well as outline of the industry have been given in the report.

In the report, the abstract section is inclusive of information on the market dynamics. This section is further categorized into driving factors propelling the market growth, industry hindrances, trends characterizing the market growth, as well as the business opportunities prevalent in the industry.

The Stem Cell Therapy Market report also contains information pertaining to the anticipated CAGR of the global business through the forecast period. In addition, many technological developments and innovations that may possibly boost the industry outlook over the anticipated period are also mentioned in the study.

Top Companies

Split by application, the market is divided into

This study is inclusive of in-depth information with respect to the consumption of the product as well as application segment market share, in tandem with the growth rate likely to be registered by every application segment.

Report Growth Drivers

What are the key highlights of this report?

More here:
Stem Cell Therapy Market Share Research By Applications And Regions - News.MarketSizeForecasters.com

2020 Exosome Technologies Market Report- Growth with Capricor, Codiak and Evox Therapeutics among Key Players – 3rd Watch News

The research reports on Exosome Technologies Market report gives detailed overview of factors that affect global business scope. Exosome Technologies Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Exosome Technologies Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1781607

Top Companies in this Report-

Capricor Therapeutics Evox Therapeutics Ltd ReNeuron Group Plc Stem Cell Medicine Ltd Tavec Inc. Codiak Biosciences Inc. Therapeutic Solutions International Inc. ArunA Biomedical Inc. Ciloa

and more

Single User License: US $ 2995

Table of Contents

1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7

2 Exosomes in Healthcare 8 2.1 Overview of Exosomes 8 2.2 Drug Delivery Systems 9 2.2.1 Modified Release Drug Delivery Systems 9 2.2.2 Targeted Drug Delivery Systems 10 2.2.3 Liposomes 12 2.2.4 Viruses 14 2.2.5 Exosomes 17 2.3 The Exosome Lifecycle 18 2.4 Exosomes in Biology 18 2.5 Exosomes in Medicine 19 2.5.1 Biomarkers 19 2.5.2 Vaccines 20 2.6 Exosomes as a Therapeutic Target 20 2.7 Exosomes as Drug Delivery Vehicles 21 2.8 Therapeutic Preparation of Exosomes 21 2.8.1 Isolation and Purification 22 2.8.2 Drug Loading 22 2.8.3 Characterization 23 2.8.4 Bioengineering 23 2.8.5 Biodistribution and In Vivo Studies 23 2.8.6 Advantages of Exosome Therapies 24 2.8.7 Disadvantages of Exosome Therapies 24 2.9 Exosomes in Therapeutic Research 25 2.9.1 Exosome Gene Therapies 25 2.9.2 Exosome in Stem Cell Therapy 26 2.10 Exosomes in Oncology 27 2.10.1 Immunotherapy 27 2.10.2 Gene Therapy 28 2.10.3 Drug Delivery 29 2.10.4 Biomarkers 30 2.11 Exosomes in CNS Disease 30 2.11.1 Tackling the Blood-Brain Barrier 30 2.11.2 Exosomes in CNS Drug Delivery 31 2.11.3 Gene Therapy 32 2.12 Exosomes in Other Diseases 33 2.12.1 Cardiovascular Disease 33 2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36 3.1 Overview 36 3.2 Exosome Pipeline by Stage of Development and Molecule Type 36 3.3 Pipeline by Molecular Target 37 3.4 Pipeline by Therapy Area and Indication 38 3.5 Pipeline Product Profiles 38 3.5.1 AB-126 ArunA Biomedical Inc. 38 3.5.2 ALX-029 and ALX-102 Alxerion Biotech 39 3.5.3 Biologics for Autism Stem Cell Medicine Ltd 39 3.5.4 Biologic for Breast Cancer Exovita Biosciences Inc. 39 3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis Regenasome Pty 39 3.5.6 Biologic for Lysosomal Storage Disorder Exerkine 39 3.5.7 Biologics for Prostate Cancer Cells for Cells 40 3.5.8 CAP-2003 Capricor Therapeutics Inc. 40 3.5.9 CAP-1002 Capricor Therapeutics Inc. 41 3.5.10 CIL-15001 and CIL-15002 Ciloa 42 3.5.11 ExoPr0 ReNeuron Group Plc 42 3.5.12 MVAX-001 MolecuVax Inc. 43 3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke Isfahan University of Medical Sciences 44 3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer Codiak BioSciences Inc. 44 3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology Evox Therapeutics Ltd 44 3.5.16 TVC-201 and TVC-300 Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48 4.1 Interventional Clinical Trials 48 4.1.1 Clinical Trials by Therapy Type 48 4.1.2 Clinical Trials by Therapy Area 49 4.1.3 Clinical Trials by Stage of Development 50 4.1.4 Clinical Trials by Start Date and Status 50 4.2 Observational Clinical Trials 51 4.2.1 Clinical Trials by Therapy Type 51 4.2.2 Clinical Trials by Therapy Area 51 4.2.3 Clinical Trials by Stage of Development 52 4.2.4 Clinical Trials by Start Date and Status 53 4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67 5.1 Company Profiles 67 5.1.1 Capricor Therapeutics Inc. 67 5.1.2 Evox Therapeutics Ltd 72 5.1.3 ReNeuron Group Plc 73 5.1.4 Stem Cell Medicine Ltd 77 5.1.5 Tavec Inc. 78 5.1.6 Codiak Biosciences Inc. 80 5.1.7 Therapeutic Solutions International Inc. 81 5.1.8 ArunA Biomedical Inc. 83 5.1.9 Ciloa 85

Read the original here:
2020 Exosome Technologies Market Report- Growth with Capricor, Codiak and Evox Therapeutics among Key Players - 3rd Watch News

Sernova Highlights Positive Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions – TheNewswire.ca

LONDON, ONTARIO - TheNewswire - June 18, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, highlights positive results from its submitted abstract entitled "Clinical Validation of the Implanted Pre-Vascularized Cell Pouch(TM) as a Viable, Safe Site for Diabetes Cell Therapy," selected for presentation at the American Diabetes Association's (ADA) 80th Scientific Sessions held virtually June 12-16, 2020.

"Sernova was honored that its abstract was selected under peer review to be presented at the prestigious ADA Scientific Sessions. The findings reported in diabetic patients, demonstrate that human donor islets transplanted into Sernova's Cell Pouch consistently demonstrate islet survival and the ability to produce the array of hormones required to treat diabetes," said Dr. Philip Toleikis, President and CEO of Sernova.

The following provides the background of our scientific presentation:

- Cellular transplantation therapy has the potential to treat severe, chronic diseases such as Type 1 Diabetes (T1D). The transplantation site and device approach are major factors influencing successful clinical outcomes;

- With new cell-based emerging technologies, there continues to be a need to find a safe, retrievable, biologically compatible device for cellular transplantation and we believe Sernova's Cell Pouch System may provide such a solution;

- The transplantation of insulin-producing islets is a cellular replacement therapy for severe T1D in patients who experience life-threatening severe hypoglycemia unawareness events;

- In this clinical indication, Sernova has conducted a physician sponsored first-in-human study in Canada and currently has an ongoing company-sponsored Phase I/II human clinical study at the University of Chicago. In both clinical studies, patients with T1D were implanted with both sentinel (small devices removed to assess cell survival) and larger therapeutic devices, anywhere between 1 to 6 months;

- After being placed on immunosuppression, islets were isolated from donor pancreata and transplanted into patients within the device chambers. When possible, a pre-transplant sample of islets was saved for comparison to post-explant Cell Pouch islets; and

- Cell Pouches were explanted from patients, anywhere between 14-90 days post-transplant. The Cell Pouches were prepared, and sections were stained and imaged, and then reviewed by an independent clinical pathologist to assess the transplanted tissue for micro-vessel formation and vascularization; the presence of islets with insulin, C-peptide, and other endocrine hormones (such as glucagon and somatostatin); and exocrine tissue (such as pancreatic ductal tissue).

The data presented clinically demonstrate that the vascularized Cell Pouch provides a consistently safe and biologically suitable, retrievable environment for the transplantation and survival of functional islets. Specific findings based on a detailed histopathological analysis of nine Sernova Cell Pouches explanted from patients with T1D diabetes include:

- Explanted Cell Pouches show abundant, viable, organized islet cells intimately associated with blood vessels within a natural collagen matrix following transplantation without obvious rejection or infection;

- 100% showed present or abundant blood vessels;

- 89% showed present or abundant insulin;

- 78% showed present or abundant endocrine cells;

- 100% showed present or abundant ductal tissue;

- Islet cells required to control diabetes within the Cell Pouches consistently express insulin and other endocrine hormones, such as glucagon, somatostatin, and C-peptide, when identified histologically;

- Pre-transplant islet samples that show strongly expressed insulin, as well as other endocrine markers, were similarly identified in the explanted Cell Pouches following transplant; and

- The amount of islet/exocrine tissue within pre-transplanted samples was similar to that found in the Cell Pouch following transplantation.

In summary, the transplanted samples, when explanted and examined, demonstrate healthy, surviving islets with multiple cell types within the islets capable of producing the hormones that control blood sugar levels when housed in the vascularized tissue matrix of the Cell Pouch. Exocrine ductal tissue, when transplanted, also survived. The findings demonstrate the pre-transplant samples are consistent with the histology observed upon explantation of the Cell Pouch at different time points. These clinical findings demonstrate that the Cell Pouch is a viable, safe site for diabetes cell therapy.

Dr. Toleikis said, "The positive results reported in patients in this diabetes indication, implanted with Sernova's Cell Pouch and transplanted with islets, continue to validate our Cell Pouch System cell therapy therapeutics approach. Within the emerging cell therapy field, Sernova, with its advancing cell therapies including locally immune protected stem cell-derived cells, continues to position itself as a leader in the development of a 'functional cure' for all patients with diabetes and other chronic diseases."

A recording of Sernova's ADA Scientific Session presentation is available at http://www.sernova.com/updates.

ABOUT SERNOVA'S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial at the University of Chicago to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova's clinical trial are incapable of producing c-peptide, a biomarker for insulin produced by islet cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, are transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regard to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients are then further followed for one year to assess longer-term safety and efficacy.

For more information on this clinical trial, please visit http://www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit http://www.pwitkowski.org/sernova.

ABOUT SERNOVA'S CELL POUCH SYSTEM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit http://www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp.

Tel: (519) 858-5126

dominic.gray@sernova.com

http://www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova's actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company's ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company's Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company's quarterly and annual filings available on http://www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Visit link:
Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions - TheNewswire.ca

Orca Bio Surfaces With $192M and Recipes for Custom Cell Therapies – Xconomy

Xconomy San Francisco

The cancer cell therapies available today are made by tweaking a patients own immune cells to better recognize and fight the disease. Orca Bio is developing what it says is the next generation of cell therapy: custom preparations made without modifying cells or genes.

Orca is already testing its technology in humans, though it has kept that research mostly under wraps. As the startup prepares to reveal its preliminary findings and ramp up its manufacturing capability, the Menlo Park, CA-based biotechannounced on Wednesday the close of $192 million in financing.

The immune system is comprised of many cells that work in concert, says CEO Ivan Dimov. Some cells stimulate activity while other cells block it. But the effects of these immune cells can be dampened by the other cells around them. Orcas therapies are allogeneictheyre made by taking stem and immune cells from healthy donors rather than from the patients themselves, as is the case with autologous treatments. But rather than just taking those healthy cells and putting them into a patient, Orca chooses certain cells from the donor sample and combines them in specific ways. Dimov says each mixture, created from certain cell types that it has assembled in the proper ratio, forms a custom immune army that seeks out cancer cells and leaves healthy tissue alone.

Weve created a novel class of precision therapiesprecise, optimal therapeutic mixtures, he says.

Orcas first disease targets are aggressive blood cancers that require bone marrow transplants as a treatment of last resort. These procedures offer patients a potential cure, but they also come with risks, such as rejection by the immune system.

In recent years, cell therapy has emerged as a new option for aggressive blood cancers that havent responded to treatment. Chimeric antigen receptor T cell therapies, or CAR-Ts, are made by engineering a patients own T cells, multiplying them in a lab, and then infusing them back into the patient to target and fight the cancer. The first CAR-Ts that reached the market were developed by Novartis (NYSE: NVS) and Gilead Sciences (NASDAQ: GILD). These therapies pose the risk of a potentially fatal immune system reaction.

There are other biotechs that are trying to advance CAR-T therapy by making it safer and more scalable. Some of them, like Orca, are developing allogeneic cell therapies. Two such companies, Allogene Therapeutics (NASDAQ: ALLO) and Precision Biosciences (NASDAQ: DTIL), use gene editing to eliminate parts of an immune cell that could prompt an adverse response. Those companies are testing their respective therapies in clinical trials.

Dimov says Orcas custom therapies are meant to allow patients to avoid the complications associated with bone marrow transplants and CAR-T drugs. The descriptor custom needs a bit of clarification: An Orca therapy is not tailored to each patient, but rather customized to generate a particular therapeutic effect, Dimov says. If it works, the right mix not only provides the optimal treatment, it also avoids any adverse immune response. This approach offers a new way to reset and rebuild the immune system, Dimov says.

Orca has two programs in clinical trials. TRGFT-201 is a formulation of T cells and regulatory T cells (a type of cell that tamps down an immune response) that is in Phase 1/2 testing in patients with certain blood cancers. A second program, OGFT-0001, is a formulation of T cells that is in Phase 1, also in blood cancers. The new cash is expected to be enough for Orca to complete Phase 1 tests of the lead program, as well as build the startups manufacturing capacity.

Preliminary data from the studies have not yet been reported but Dimov says a terminally ill cancer patient who received one of the Orca therapies got well enough to leave the hospital. Anecdote aside, while full data are expected in 2022, some early findings are being prepared for peer review.

Orca traces its origins to the laboratory of Irv Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Dimov joined Weissmans group in 2010 as the field of cell therapy was heating up. At that time, a central obstacle to its progress was figuring out how to make cell therapy manufacturing scalable. Meanwhile, the scientific communitys understanding of immune cells continued to advance. Orcas intellectual property covers both the cell therapy manufacturing technology, which offers the capability to sort stem and immune cells, and the therapeutic mixtures of cells. The startup spun out of Stanford in 2016 and started its first clinical trial about two years later, Dimov says.

Though cancer is Orcas focus for now, Dimov says the companys technology has potential applications in other diseases. Rare inherited disorders such as beta thalassemia and severe combined immunodeficiency are possible targets. Autoimmune diseases represent another opportunity. For each one, Orca would develop an appropriate mixture of immune and stem cells to treat the condition and restore immune system function, Dimov says.

Including the latest financing, Dimov says Orca has raised nearly $300 million. The new capital, a Series D round of funding, was co-led by Lightspeed Venture Partners and an unnamed investor. The other investors Orca has disclosed are 8VC, DCVC Bio, ND Capital, Abu Dhabi sovereign wealth fund Mubadala Investment Company, Kaiser Permanente, and the Illinois Municipal Retirement Fund.

Image: iStock/jonmccormackphoto

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

View post:
Orca Bio Surfaces With $192M and Recipes for Custom Cell Therapies - Xconomy

Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO – Webster County Citizen

ST. LOUIS, June 18, 2020 /PRNewswire/ -- OpenCell Technologies, an R&D-stage biomedical venture, has announced the hiring of Kevin Gutshall as CEO. Kevin leaves his role as MilliporeSigma's director of life science business development and M&A focusing on the cell and gene therapy business unit, to join OpenCell and lead its efforts to translate and commercialize its core technology platform, POROS.

OpenCell was established based on technology developed at the Georgia Institute of Technology, by Engineering faculty and company co-founders Mark Meacham, PhD, Andrei Fedorov, PhD, and Levent Degertekin, PhD. Dr. Meacham was subsequently recruited to Washington University in St. Louis, and OpenCell relocated to the BioGenerator Labs in the Cortex Innovation Community adjacent to the Washington University School of Medicine. The company's core technology, which has broad applications ranging from fuel and energy to life sciences, is focused on the rapidly emerging cell and gene therapy market.

"I am thrilled to join OpenCell, as it is now poised to move from an R&D stage to a commercial business," said Gutshall. "I believe that the POROS platform will be a disruptive technology platform in the cell and gene therapy marketplace."

During its seed stage, the company benefitted from BioGenerator Entrepreneurs-in-Residence (EIR) that brought key expertise to the company as it pivoted from the research tools market to cell and gene therapy applications. Paul Olivo, MD, PhD, a former BioGenerator EIR and current Venture Partner at Synchrony Bio, which also participated in the current financing, serves as a key advisor to OpenCell, managing the company's research team. In her role as BioGenerator EIR, Heather Holeman, PhD, now CEO of Lifespan Biosciences, facilitated key business development connections for the company. Concurrent with the financing, Charlie Bolten, Senior Vice President of BioGenerator, joins OpenCell's board of directors.

"Together with Synchrony Bio, BioGenerator's investment in OpenCell is the culmination of extensive due diligence and hands-on support by our investment, Entrepreneur-in-Residence and Grants-2-Business teams," said Bolten. "With the successful recruitment of a CEO with deep experience in commercialization, business development and M&A, we are pleased to see OpenCell take an important step toward commercializing the POROS platform."

"I am excited to welcome Kevin as the new CEO of OpenCell," added Chad Stiening, OpenCell Executive Chairman and Managing Director at Synchrony Bio. "His professional background and personal passion in the cell and gene therapy space is a perfect fit for the company as it seeks to realize the full potential of its technology and enable the development and manufacturing of promising new therapies in this dynamic market."

In addition to investments from BioGenerator and Synchrony Bio, the company has leveraged significant Federal grant funding over $3M total to help secure equity financing and achieve key milestones that helped attract strategic partnering interest as well as its new CEO.

About OpenCellOpenCell Technologies provides efficient, high-throughput and scalable transfection tools to the Life Science Industry, enabling it to use difficult-to-transfect cells (e.g., primary and cancer stem cell cultures) in development of cell-based analysis techniques and discovery of new therapeutic cell-based therapies. Unlike currently available products, the OpenCell technology features precise control of biophysical actions on a single-cell basis without sacrificing throughput. OpenCell's vision is to realize a novel, cost-effective approach to transfection that will overcome existing research and development obstacles.Our mission is to make cellular therapies effective, affordable and scalable for the clinical and research communities. Visit opencelltech.com for more information.

About BioGenerator BioGenerator, the investment arm of BioSTL, produces a sustained pipeline of successful bioscience companies and entrepreneurs in St.Louis by creating, growing and investing in promising new enterprises. Visit biogenerator.org for additional information, and follow us on LinkedIn and Twitter.

About Synchrony BioSynchrony Bio seeks to achieve consistently superior investor returns in early-stage biomedical and life science ventures by aligning seasoned talent, staged investment capital, and process efficiencies.Careful and coordinated alignment of all three is key to overcoming unique challenges faced by medical device and diagnostics ventures, in order to realize significant upside and superior returns.Synchrony's extended network of experts and advisors includes professionals with deep, cross-functional experience and backgrounds. Visit synchronybio.com for additional information.

Go here to read the rest:
Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO - Webster County Citizen